Evidence map›Paper›PMID 36635088›Full record

ArticleJournal of nuclear medicine : official publication, Society of Nuclear Medicine2023

Developing a Patient-Reported Outcome Measure for Radionuclide Therapy for Prostate Cancer.

Lisa M Gudenkauf, Melody N Chavez, Melinda Leigh Maconi, Carley Geiss, Ameen Seyedroudbari, Pan Thin, Aasha I Hoogland, Kathleen Nguyen, Vishnu Murthy, Wesley R Armstrong and 13 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
4.6field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 20 citations in OpenAlex.

  1. Phase 2 Prospective Trial of Retreatment with [Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026
    Trial
  2. Article
  3. Article
  4. Randomized Phase 2 Trial of an Extended and Flexible Dosing Schedule ofJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025
    Article
  5. Article
  6. Review
  7. Best Patient Care Practices for Administering PSMA-Targeted Radiopharmaceutical Therapy.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 8 institutions in 3 countries.

Lisa M GudenkaufDepartment of Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, Florida; lisa.gudenkauf@moffitt.org.
Melody N ChavezParticipant Research, Interventions, and Measurements Core, Moffitt Cancer Center, Tampa, Florida.
Melinda Leigh MaconiParticipant Research, Interventions, and Measurements Core, Moffitt Cancer Center, Tampa, Florida.
Carley GeissParticipant Research, Interventions, and Measurements Core, Moffitt Cancer Center, Tampa, Florida.
Ameen SeyedroudbariDepartment of Molecular and Medical Pharmacology, UCLA, Los Angeles, California.
Pan ThinDepartment of Molecular and Medical Pharmacology, UCLA, Los Angeles, California.
Aasha I HooglandDepartment of Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, Florida.
Kathleen NguyenDepartment of Molecular and Medical Pharmacology, UCLA, Los Angeles, California.
Vishnu MurthyDepartment of Molecular and Medical Pharmacology, UCLA, Los Angeles, California.
Wesley R ArmstrongDepartment of Molecular and Medical Pharmacology, UCLA, Los Angeles, California.
Khaled KomrokjiDepartment of Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, Florida.
Laura B OswaldDepartment of Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, Florida.
Heather S L JimDepartment of Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, Florida.
Ghassan El-HaddadDepartment of Diagnostic Imaging and Interventional Radiology, Moffitt Cancer Center, Tampa, Florida.
Wolfgang P FendlerDepartment of Nuclear Medicine, University of Duisburg-Essen, and German Cancer Consortium-University Hospital Essen, Essen, Germany.
Ken HerrmannDepartment of Nuclear Medicine, University of Duisburg-Essen, and German Cancer Consortium-University Hospital Essen, Essen, Germany.
David CellaDepartments of Medical Social Sciences and Psychiatry and Behavioral Sciences, and Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
Johannes CzerninDepartment of Molecular and Medical Pharmacology, UCLA, Los Angeles, California.
Michael S HofmanProstate Cancer Theranostics and Imaging Centre of Excellence, Cancer Imaging, Peter MacCallum Centre, Melbourne, Victoria, Australia, and MacCallum Department of Oncology, University of Melbourne, Melbourne, Victoria, Australia.
Adam P DickerDepartment of Pharmacology and Experimental Therapeutics, Sidney Kimmel Cancer, Thomas Jefferson University, Woodbury, New Jersey; and.
Jeremie CalaisDepartment of Molecular and Medical Pharmacology, UCLA, Los Angeles, California.
Scott T TagawaDepartment of Urology, Weill Cornell Medical College, New York, New York.
Brian D GonzalezDepartment of Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, Florida.
Moffitt Cancer Center · USUniversity of California, Los Angeles · USEssen University Hospital · DECornell University · USNorthwestern University · USPeter MacCallum Cancer Centre · AUSidney Kimmel Cancer Center · USUCLA Health · US

Funding

UCLA SPORE in Brain CancerP50CA211015 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Yvonne Yu-Hsuan Chen · 2017 to 2026
$25.2M
NCI NIH HHS P50 CA211015
6 · The paper itself

Abstract

The field of radionuclide therapy (RNT) for prostate cancer (PC) is growing rapidly, with recent Food and Drug Administration approval of the first

Indexed as

Prostatic NeoplasmsHumansMalePatient Reported Outcome MeasuresRadioisotopesRadioisotopesgenitourinary oncologypatient-reported outcomesprostate cancerradionuclide therapyradiopharmaceuticals

Identifiers

PMID36635088
PMCPMC10241017
OpenAlexW4315750287

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.